In the search for new oximes with higher reactivation potency and a broader spectrum, K-27 and K-48, have recently been synthesized. To test if their superior efficacy was related to better penetration across the blood-brain barrier, their brain entry was compared with that of obidoxime, when administered either alone or after the organophosphate paraoxon (POX). Rats received 50 μmol obidoxime, K-27 or K-48, either alone or in addition to 1 μmol POX. Oxime concentrations at various points in time in brain and plasma were measured using HPLC. The obidoxime Cmax in brain was 1.3% of the plasma Cmax when injected alone, and 1.5% when injected following POX. The ratio of the area under the curve (AUC) brain to plasma for obidoxime was around 6%, irrespective of whether it was administered alone or after POX. For K-27, Cmax (brain) was 0.6% of Cmax (plasma) when injected alone, and 0.7% when injected after POX (no significant difference). The AUC (brain) was 2% of AUC (plasma) for both K-27 groups. K-48, when injected alone reached 1.4% of Cmax (plasma) in the brain and 1.2% of C max (plasma), when injected following POX. The AUC (brain) was 5% of the AUC (plasma), both when K-48 was administered alone and in combination with POX. Entry of all three oximes into the brain is minimal and cannot explain the better therapeutic efficacy of K-27 and K-48. As already observed for pralidoxime, injection of POX before oxime administration had no influence upon penetration across the blood-brain barrier.
|Number of pages||9|
|Journal||Journal of Applied Toxicology|
|Publication status||Published - Sept 2007|
- Blood-brain barrier
ASJC Scopus subject areas